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Keishibukuryogan (KBG) is one of the traditional herbal formulations widely administered to patients with blood stagnation for
improving blood circulation; currently, it is the most frequently prescribed medicine in Japan. KBG has been reported to improve
conjunctional microcirculation. The aim of this study was to evaluate the role of KBG and paeoniﬂorin, a bioactive compound
of KBG, in inhibiting the production of inﬂammatory cytokines using human dermal microvessel endothelial cells (HDMECs).
The authors observed that lipopolysaccharide (LPS; 1μg/mL) stimulated the secretion of proinﬂammatory cytokines in HDMECs.
KBG treatment (10mg/mL) signiﬁcantly suppressed the mRNA levels of migration inhibitory factor (MIF), interleukin (IL)-6, IL-
8, and tumor necrosis factor (TNF)-α in LPS-stimulated cultured HDMECs. Similarly, paeoniﬂorin signiﬁcantly suppressed the
mRNA levels of these cytokines in LPS-stimulated cultured HDMECs. ELISA showed that KBG and paeoniﬂorin suppressed the
production of MIF, IL-6, IL-8, and TNF-αin LPS-stimulated HDMECs.Moreover, KBGand paeoniﬂorin decreased the expression
of cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) in these cells. These results suggest that KBG may be useful for
improving microvascular inﬂammation in patients with skin diseases.
1.Introduction
Keishibukuryogan (KBG, Gui-zhi-fu-ling-wan in Chinese) is
one of the Kampo medicines, and has been widely adminis-
tered to patients with blood stagnation for improving blood
circulation. KBG is now one of the most frequently used
medicines in Japan. KBG has been used clinically to treat
various diseases, including skin diseases. It was reported that
KBG improves conjunctional microcirculation in patients
with cerebrospinal vascular diseases [1], thus suggesting that
it may have beneﬁcial eﬀects on hematological parameters
such as blood viscosity and red blood cell deformability
[2–4]. Moreover, Matsumoto et al. have explored a pro-
teomic approach for the diagnosis of blood stasis in rheuma-
toidarthritispatientstreatedwithKBG[5].Inaddition,KBG
is used to treat symptoms of peripheral ischemia such as cold
extremities [6]. Furthermore, we recently reported that KBG
is eﬀective in patients with chronic pigmented purpura, a
group of skin vascular disorders of unknown etiology [7].
KBGiscomposedofﬁvemedicinalplants,Cinnamomum
cassia Blume (Cinnamomi cortex), Paeonia lactiﬂora Pallas
(Paeoniae Radix), Paeonia suﬀruticosa Andrews (Moutan
cortex), Prunus persica Batsch (Persicae semen) and Poria
cocos Wolf (Hoelen) (Table 1)[ 8]. Paeoniae Radix and
Moutan Cortex have many known active components in
common, including paeoniﬂorin, paeonol, oxypaeoniﬂorin,
benzoylpaeoniﬂorin, and palbinone [9]. Paeoniﬂorin is a
characteristic main principal bioactive component of Paeo-
niae Radix, which included approximately 5.57% (w/w)
paeoniﬂorin, and Moutan Cortex, which included approx-
imately 3.96% (w/w) paeoniﬂorin [10]. Paeoniﬂorin has
been reported to have many pharmacological eﬀects, such
as anti-inﬂammatory and antiallergic eﬀects [11]. Recently,
Zheng and Wei reported that the total glucosides present2 Mediators of Inﬂammation
Table 1: Components of keishibukuryogan (KBG).
Japanese name Scientiﬁc name Botanical name Ratio (g)
Keihi Cinnamomi cortex Cinnamomum
cassia Blume
1
Syakuyaku Paeoniae radix Paeonia
lactiﬂora Pallas
1
Tounin Persicae semen Prunus persica
Batsch
1
Bukuryou Hoelen Poria cocos Wolf 1
Botanpi Moutan cortex
Paeonia
suﬀruticosa
Andrews
1
in the Moutan Cortex, which contain paeoniﬂorin as the
principle bioactive component, inhibited primary and sec-
ondary inﬂammation in both collagen-induced arthritis and
adjuvant-induced arthritis [12].
Up until now, topical and oral corticosteroids, oral
bioﬂavonoids, ascorbic acid, griseofulvin, and cyclosporine
have been suggested as treatments for chronic pigmented
purpura [13, 14]. However, none of these treatments have
proven to be satisfactory. Human dermal microvessel
endothelial cells (HDMECs) are the prominent cells in der-
mal skin. HDMECs produce inﬂammatory cytokines, such
as interleukin (IL)-6 and IL-8 when they are exposed
to lipopolysaccharide (LPS). We therefore consider that
examinations of the eﬀects of KBG and paeoniﬂorin on
HDMECs are important for the therapeutic studies of
chronic pigmented purpura in vitro.
In this study, we aimed to evaluate the role of KBG and
paeoniﬂorin, ininhibiting the production of inﬂammatory
cytokines using HDMECs.
2.MaterialsandMethods
2.1. Materials. KBG (TJ-25) was obtained from Tsumura &
Co. (Tokyo, Japan). KBG was suspended in CS-C complete
medium containing 10% fetal calf serum and 1% peni-
cillin and CSC growth factor (Cell Systems Inc, WA) and
was rotated at 4◦C overnight [11]. Then, the suspension
was centrifuged, and the supernatant was ﬁltered through
a0 . 4 5 μm-pore membrane. The following materials were
obtained from commercial sources: the Isogen RNA extrac-
tion kit was obtained from Nippon Gene (Tokyo, Japan);
M-MLV reverse transcriptase was from GIBCO (Grand
Island, NY); Taq DNA polymerase was from Perkin-Elmer
(Norwalk, CO); LPS was purchased from Sigma (St. Louis);
nylon membranes were from Schleicher & Schuell (Keene,
NH);theanticyclooxygenase-2(COX-2)polyclonalantibody
(pAb) was purchased from Cell Signaling Technology, Inc.
(Boston); antiinducible NOS (iNOS) pAb was purchased
from Enzo Life Sciences International Inc. (NY); the anti-β-
actin Ab was purchased from Santa Cruz Biotechnology Inc.
(CA); Paeoniﬂorin was from LKT Laboratories, Inc.; MIF,
IL-6, and IL-8 ELISA kits were obtained from R&D Systems
(Minneapolis); and the Western blot detection system was
obtained from Cell Signaling Technology (Beverly, MA). All
other reagents were of analytical grade.
2.2. Cell Stimulation. Primary human dermal endothelial
cells (HDMECs) were obtained from Cell Systems Inc (WA).
HDMECs were cultivated in conditioned endothelial culture
medium (CS-C complete medium) containing 10% fetal calf
serum and 1% penicillin and CSC growth factor at 37◦Ci n
a5 %C O 2 atmosphere. Cell viability before treatment was
always over 95% as evaluated by Trypan blue dye exclusion
test. On the day of the experiment, cells were collected
and suspended in fresh culture medium at a concentration
of 1×106 cells/mL. The cells were divided into 4 groups:
a control group, a group receiving 10mg/mL of KBG or
100μg/mL of paeoniﬂorin as previously described [9, 15],
ag r o u pt r e a t e dw i t h1 μg/mL of LPS, and another group
treated with the combination. The cells were treated with the
various agents, and analyses were performed as described for
each procedure.
2.3. MTT Assay. The number of cells was measured by an
MTT assay. In brief, the media were removed by aspiration,
and then the cells were treated with 0.5mg/mL dimethylthi-
azol-2-yl-2,5-diphenyltetrazolium bromide (MTT, Sigma) in
culturemediumfor4hoursat37◦C.Afterbeingwashedwith
PBS once, isopropanol/0.04M HCl was added, and OD570
was measured, and the value of blank was subtracted.
2.4. Reverse Transcription-PCR Analysis. Total RNA was
extractedfromeachmouseskinspecimen.RNAreversetran-
scription was performed with M-MLV reverse transcriptase
using random hexamer primers, and subsequent ampliﬁca-
tion was done using Taq DNA polymerase. PCR was carried
out for 30 cycles with denaturation at 94◦C for 30seconds,
annealing from 52 to 64◦C for 1minute and extension at
72◦C for 30seconds using a thermal cycler (PE Applied
Biosystems Gene Amp PCR system 9700). The human MIF
primers used were 5
 -ATGCCGATGTTCATCGTAAAC-3
 
(forward) and 5
 -GGCGAAGGTGGAGTTGTTCCA-3
 
(reverse). The IL-6 primers used were 5
 -GATGCAATA-
ACCACCCCTGACCC-3
  (forward) and 5
 -CAATCTGAG-
GTGCCCATGCTAC-3
  (reverse). The IL-8 primers used
were 5
 -CATGACTTCCAAGCTGGCCGTG-3
  (forward),
5
 -CCACTCTCAATCACTCTCAGTTC-3
  (reverse) [16].
The TNF-α primers used were 5
 -ACACCGTCAGCCGAT-
TTGC-3
  (forward) and 5
 -CCCTGAGCCATAATCCCC-
TT-3
  (reverse). GAPDH was used as a positive control.
The primers used were 5
 -ACCCAGAAGACTGTGGAT-3
 
(forward) and 5
 -TCGTTGAGGGCAATGCCA-3
  (reverse).
After PCR, the ampliﬁed products were analyzed using 2%
agarose gel electrophoresis.
2.5. Cytokine Release Measurements. Supernatants were col-
lected after 24h of incubation with LPS (1μg/mL) and/or
KBG (10mg/mL) and paeoniﬂorin (100μg/mL). MIF, IL-6,
and IL-8 were assayed by ELISA, according to the manu-
facturer’s instructions. The absorbance was measured with
a microplate reader (Labsystems Multiskan Bichromatic).Mediators of Inﬂammation 3
2.6. Western Blot Analysis. Cells were collected and washed
with cold PBS. The cells were lysed at a density of
1×106 cells/50μLo fR I P Ab u ﬀer (1M Tris-HCA, 5M NaCl,
1% Nonidet P-40 (v/v), 1% sodium deoxycholate, 0.05%
SDS, 1mM phenylmethyl sulfonyl ﬂuoride) for 20minutes.
After brief sonication, the lysates were centrifuged at
12,000rpm for 10minutes at 4◦C, and the protein content
in the supernatants was measured using a bio-rad protein
assay kit (Bio-Rad, Hercles, CA). The protein lysates were
denaturedat96◦Cfor5minaftermixingwith5μLofsodium
dodecylsulfate (SDS) loading buﬀer, applied on an SDS
polyacrylamide gel for electrophoresis, and transferred to
nitrocellulose membranes. Western blot analysis was carried
out to detect the expression levels of COX-2 and iNOS
using speciﬁc antibodies [17]. Band signals were visualized
on X-ray ﬁlm using chemiluminescence ECL detection
reagents (Amersham Biosciences, Buckinghamshire, UK).
The relative amounts of proteins associated with speciﬁc
antibodies were normalized according to the intensities of β-
actin.
2.7. Statistical Analysis. The values are expressed as the
means ± SD of the respective test or control group.
Statistically signiﬁcant diﬀerences in the stimulation with
LPS in the groups treated with KBG or paeoniﬂorin were
evaluated by the nonparametric Mann-Whitney U test. P-
values of <.05 were considered to be statistically signiﬁcant.
3. Results
3.1. The Eﬀects of KBG on LPS-Stimulated Induction of
Cytokines in HDMECs. LPS plays a fundamental role in the
pathogenesisofanumberofinﬂammatorydiseasesbyinduc-
ingadistinctivepatternofinﬂammatorycytokinerelease.We
used LPS to produce inﬂammatory conditions in HDMECs.
The cells were incubated with or without 1μg/mL of LPS
or 10mg/mL of KBG for 6 or 24h, and the cell viability
was assessed. None of the treatments elicited cytoxicity in
the cells at the tested concentrations and incubation times
(Figure 1(a)). We examined the anti-inﬂammatory eﬀects
of KBG on the induction of inﬂammatory cytokines by
LPS stimulation. LPS-induced protein levels of MIF, IL-
6, IL-8, and TNF-α were signiﬁcantly inhibited by KBG
(Figure 1(b)) .T r e a t m e n to ft h ec e l l sw i t h1 μg/mL of LPS
increased in mRNA levels of these cytokines from 6h after
stimulation, but these mRNA levels were decreased by KBG
(Figure 1(c)).
3.2. Eﬀect of Paeoniﬂorin on LPS-Stimulated Induction of
Cytokines in HDMECs. The cells were incubated with or
without 1μg/mL of LPS or 100μg/mL of paeoniﬂorin for 6
or 24h, and the cell viability was assessed. Figure 2(a) reveals
that the incubation with paeoniﬂorin did not elicit toxicity
in cells at the tested concentration at either incubation
time. LPS-induced protein levels of MIF, IL-6, IL-8, and
TNF-α were signiﬁcantly inhibited by paeoniﬂorin, and the
inhibitoryeﬀectwasstrongerthanthatofKBG(Figure 2(b)).
Moreover, to examine the eﬀects of paeoniﬂorin on the
mRNA levels of inﬂammatory cytokines, cells were treated
withLPSfor6hinthepresenceof100μg/mLofpaeoniﬂorin.
The LPS-induced MIF, IL-6, IL-8, and TNF-α mRNA levels
were decreased by paeoniﬂorin (Figure 2(c)).
3.3. Inhibition of COX-2 and iNOS Protein Expression by
Paeoniﬂorin. Next, we examined whether paeoniﬂorin could
inhibit the production of COX-2 and iNOS. Western blot
analyses revealed that the expression of COX-2 and iNOS
was increased by LPS stimulation in HDMECs whereas the
treatment with paeoniﬂorin resulted in a decrease in COX-2
and iNOS expression (Figure 3).
4. Discussion
Among traditional Japanese medicinal compounds, Kampo
formulas originated from ancient Chinese medicine, and are
currently recognized and reimbursed by the Health Ministry
in Japan for the treatment of a wide variety of conditions.
The Kampo formula KBG is frequently used in traditional
Japanese and Chinese medicine to treat several symptoms,
including skin diseases. The preparation has demonstrated
anti-inﬂammatory and free-radical scavenging eﬀects.
In the present study, we have demonstrated that KBG
treatment signiﬁcantly suppressed the protein and mRNA
levels of MIF, IL-6, IL-8, and TNF-α in LPS-stimulated
cultured HDMECs. Chronic pigmented purpura is a dis-
ease complex characterized by capillaritis and lymphocytic
capillary damage in the papillary dermis. Several lines of
evidence suggest the involvement of humoral or cellular
immunity, as well as hemostasis, in the pathogenesis of
this disease [18]. These patients are sometimes resistant
to standard treatments, such as topical corticosteroids.
Indeed, our previous data support the eﬀectiveness of KBG,
which led to a signiﬁcant improvement in patients with
chronic pigmented purpura [7]. It is reported that KBG
can prevent the progression of atherosclerosis [19], and
preserve vascular endothelial function in cholesterol-fed
rabbits [19] and in hypertensive rats [20]. Furthermore, in
diabetic rats, it was demonstrated to have protective eﬀects
against vascular injury [21], and to delay the development
of diabetic kidney disease [22, 23]. Moreover, KBG has a
favorable eﬀect on impaired glucose metabolism in type
2 diabetes by improving glucose intolerance, and it has
been suggested that some of this eﬀect is derived from
the reduction of TNF-α content in skeletal muscle [24].
Accordingly, KBG may exert beneﬁcial eﬀects that result
in the inhibition of inﬂammatory cytokines in HDMECs.
It was recently reported that MIF induces the endothelial
expression of IL-8, thus resulting in leukocyte recruitment
[25]. Since MIF is an initiator of other proinﬂammatory
cytokines such as IL-6, IL-8, and TNF-α, and regulates
the induction of these cytokines [26, 27], we hypothe-
sized that KBG may inhibit MIF-regulated inﬂammatory
mediators.
Wealsodemonstratedthatpaeoniﬂorin,abioactivecom-
pound contained in KBG, suppressed the mRNA levels of
these inﬂammatory cytokines in LPS-stimulated cultured
HDMECs, similar to the eﬀects of KBG. It is known that
paeoniﬂorinhasanti-inﬂammatoryandantiallergicactivities4 Mediators of Inﬂammation
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Figure 1: Eﬀect of KBG on LPS-stimulated induction of cytokines in HDMECs. (a) HDMEC cells were treated with 1μg/mL LPS and/or
KBG (10mg/mL) for 6 or 24h and were subjected to the MTT assay. (b) HDMEC cells were treated with 1μg/mL LPS and/or 10mg/mL of
KBG for 24h. The MIF, IL-6, IL-8, and TNF-α content of cultured supernatants was analyzed by ELISA. Data are presented as the means ±
S.D (n=5). ∗P < .001, ∗∗P < .005, ∗∗∗P < .05. (c) The cells were treated with 1μg/mL LPS and/or 10mg/mL of KBG for 6h. Total RNA
was isolated, and the mRNA expression levels of MIF, IL-6, IL-8, and TNF-α were detected by RT-PCR. (These experiments were repeated
three times with similar results).Mediators of Inﬂammation 5
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Figure 2: Eﬀect of paeoniﬂorin on LPS-stimulated induction of cytokines in HDMECs. (a) HDMEC cells that were treated with LPS
(1μg/mL) and/or paeoniﬂorin (100μg / m L )f o r6o r2 4ha n dw e r es u b j e c t e dt ot h eM T Ta s s a y .( b )H D M E Cc e l l sw e r et r e a t e dw i t h1μg/mL
LPS and/or 100μg/mL of paeoniﬂorin for 24h. The MIF, IL-6, IL-8, and TNF-α protein content of cultured supernatants was analyzed
by ELISA. Data are presented as the means ± S.D (n = 5). ∗P < .0005. (c) The cells were treated with 1μg/mL LPS and/or 100μg/mL of
paeoniﬂorin for 6h. Total RNA was isolated, and the mRNA expression levels of MIF, IL-6, IL-8, and TNF-α were detected by RT-PCR.
(These experiments were repeated three times with similar results).6 Mediators of Inﬂammation
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Figure 3: Eﬀect of paeoniﬂorin COX-2 and iNOS protein expression. HDMEC cells were treated with 1μg/mL LPS and/or 100μg/mL
of paeoniﬂorin for 24h. COX-2 and iNOS protein expression in the cells was detected by a Western blot analysis, using β-actin as the
internal control. The results of densitometric analysis, normalized with respect to β-actin using a bioimaging analyzer, are presented. Data
are presented as the means ± S.D (n = 5). ∗P < .0001. (This experiment was repeated three times with similar results).
[28, 29]. In addition, paeoniﬂorin has reportedly exhibited
immunoregulatory eﬀects [30, 31], analgesic eﬀects [32],
neuromuscular blocking [33, 34], cognition enhancement
[35], and steroid protein binding inhibition [36]. Our study
revealed that paeoniﬂorin decreased the expression of COX-
2 and iNOS in HDMECs. Many studies have demonstrated
that overproduction of nitric oxide and inﬂammatory
prostaglandins such as PGE2, mainly via iNOS and COX-
2, respectively, plays an important pathophysiological role
in the development of inﬂammation [37]. Kim and Ha
reported that paeoniﬂorin treatment signiﬁcantly attenuated
LPS-induced NO and PGE2 production [38]. Moreover, the
extract of KBG has been shown to have COX-2 and inducible
iNOS inhibitory activities [39]. In this context, we suggest
that KBG and paeoniﬂorin induce their anti-inﬂammatory
eﬀects by inhibiting both proinﬂammatory cytokines and
inhibiting the cascade of the overproduction of COX-2 and
iNOS in HDMECs.
5. Conclusion
Taken altogether, these ﬁndings suggest that KBG may be
useful to improve microvascular inﬂammation in patients
with skin diseases such as chronic pigmented purpura.
Nonstandard Abbreviations:
ELISA: Enzyme-linked immunosorbent assay
HDMECs: Human dermal microvessel endothelial cells
KBG: Keishibukuryogan
IL: Interleukin
LPS: Lipopolysaccharide
MIF: Migration inhibitory factor
TNF: Tumor necrosis factor.
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